Aptose Biosciences Climbs 17% to Reclaim Some Losses

Aptose Biosciences (TSX:APS)(NASDAQ:APTO) recovered 17% after losing 45% this week from results of its drug trial gave investors a wait-and-see report.

| More on:

Aptose Biosciences (TSX:APS)(NASDAQ:APTO) shares climbed 17% on Thursday after losing up to 45% earlier this week. This came after the company announced results from its leukemia drug trial.

What happened?

Shares of Aptose were already in free fall before this recent selloff. The company saw shares drop from 52-week highs of $9 per share, down to $1.39, a loss of 85%. Since that time, shares have recovered only slightly to $1.76 as of writing.

This recent selloff comes after the company reported its luxeptinib drug trial showed “meaningful benefit in all responders” of its 34-patient study. The area aims to help treat acute myelogenous leukemia (ACL) relapses, where treatment remains difficult.

The problem is two-fold, however. Aptose now must wait for its phase two of the trial to begin in the first half of 2022, and it was a small study to begin with. So, investors are left with yet another wait-and-see situation.

So what?

The recent dropoff meant other investors saw the fall as an opportunity. And that’s the angle some analysts believe they should take. The last report left investors with lukewarm results as well back in June, but analysts now recommend it as a strong long-term hold.

Yet in this post-recovery world, where investors want the next big thing after the COVID-19 vaccine, it seems some aren’t willing to wait. That puts the stock in a continued volatile situation — even after this 17% gain.

After all, 17% isn’t much when you’re trading at about $1.75.

Now what?

If you’re willing to watch Aptose consistently for signs of improvement, this could be a great momentum buy. Now is a prime example as it recovers some losses. In fact, one analyst recently increased his target price from $9 to $14, coming from strong quarterly results that beat expectations. That’s a potential upside of 713% as of writing! They also are optimistic about this new drug, with 30-fold more potency.

So, if you believe that Aptose could eventually recover from these enormous losses, analysts continue to recommend it as a solid long-term buy. But if you’re looking for the next big thing after the vaccine, you might be waiting a bit longer.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Investing

An investor uses a tablet
Stocks for Beginners

If I Could Only Buy 2 Stocks in the Last Half of 2024, I’d Pick These

I’m looking to buy two stocks over the next month. Here’s a look at my picks and why you should…

Read more »

gift is bigger than the other
Investing

Millennials: 1 Growth Stock Set to Shine in 2025

Shopify (TSX:SHOP) stock could be worth betting on as it goes for growth in the new year!

Read more »

up arrow on wooden blocks
Stock Market

2 Stocks I’ll Be Adding to My RRSP — Even With the TSX at All-Time Highs

Calian Group and Pan American Silver are two TSX stocks trading at an attractive multiple that can generate market-beating returns…

Read more »

dividends can compound over time
Investing

Here Are My Top 2 TSX Stocks to Buy Right Now

Shares of these fundamentally strong TSX companies have significant room for further growth, making them compelling investments right now.

Read more »

A worker drinks out of a mug in an office.
Dividend Stocks

Is Brookfield Infrastructure Partners a Buy for its 4.75% Yield?

Brookfield Infrastructure Partners (BIP) has a 4.75% dividend yield. Is it worth it?

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Monday, November 4

In addition to the ongoing corporate earnings season, the U.S. presidential election and the Federal Reserve’s interest rate decision could…

Read more »

calculate and analyze stock
Investing

2 Top Value Stocks I’d Happily Scoop Up in November

Here are two top value stocks I'm seriously considering adding this month. They are likely to continue to accumulate over…

Read more »

A data center engineer works on a laptop at a server farm.
Tech Stocks

3 No-Brainer Data Centre Stocks to Buy With $500 Right Now

Data centres are going to be a huge growth opportunity in the next decade. And these are the top buys.

Read more »